PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

Armida D’Incecco; Mariacarla Andreozzi; Vienna Ludovini; Elisa Rossi; Alessandra Capodanno; Lorenza Landi; Carmelo Tibaldi; Gabriele Minuti; Jessica Salvini; Erika Coppi; Antonio Chella; Gabriella Fontanini; Marco Filice; Luigi Tornillo; Roberto Incensati; Spartaco Sani; Lucio Crinò; Luigi Terracciano; Federico Cappuzzo

doi:10.1038/bjc.2014.555

Abstract

PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.

Keywords

KRASGefitinibLung cancerMedicineErlotinibPD-L1AdenocarcinomaImmunohistochemistryOncogeneInternal medicineHistologyOncologyCancer researchEpidermal growth factor receptorCancerImmunotherapyCell cycleColorectal cancer

Affiliated Institutions

Related Publications

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Joseph F. Grosso , Christine E. Horak , David Inzunza +15 more

3016 Background: The immune checkpoint receptor programmed death-1 (PD-1) negatively regulates T-cell activation. In a phase I study, nivolumab, a PD-1 receptor blocking antibod...

2013 Journal of Clinical Oncology 158 citations

Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study

Yanbin Chen , Chuanyong Mu , Jian‐An Huang

Aims and background The programmed death-1-ligand 1 (PD-L1) has been recently suggested to play a pivotal role in the immune evasion of tumors from host immune system. In the st...

2012 Tumori Journal 216 citations

B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer

Scott Gettinger , Roy S. Herbst

Over the past few years, there has been a mounting enthusiasm around the potential of immunotherapy in the treatment of non-small cell lung cancer (NSCLC). This interest was cat...

2014 The Cancer Journal 65 citations

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis , Michael E. Goldberg , Danielle Greenawalt +66 more

Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups o...

2018 Cancer Discovery 1505 citations

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi , Francisco Sánchez-Vega , Konnor La +29 more

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of pati...

2018 Journal of Clinical Oncology 1371 citations

Publication Info

Year: 2014
Type: article
Volume: 112
Issue: 1
Pages: 95-102
Citations: 597
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

597

OpenAlex

Cite This

APA Style

                            
                                
                                    Armida D’Incecco, 
                                
                                    Mariacarla Andreozzi, 
                                
                                    Vienna Ludovini
                                
                                et al.
                            
                            (2014). 
                            PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. 
                            British Journal of Cancer
                            , 112
                            (1)
                            , 95-102.
                            https://doi.org/10.1038/bjc.2014.555
                        

Identifiers

DOI: 10.1038/bjc.2014.555